Stefano Ferrari - Concepedia

Author

Stefano Ferrari

Also Known As

FERRARI, Stefano, Ferrari Stefano, Ferrari, Stefano, Ferrari, Stefano; Università Di Bologna, H. Özger, S A Ferrari, S Ferrari, S. A. Ferrari, S. FERRARI, S. Ferrari

287

Publications

17.6K

Citations

H-Index

Concepts

All Affiliations

Istituto Ortopedico Rizzoli Fondazione IRCCS Istituto Nazionale dei Tumori University of Bologna Ospedale Regina Margherita Candiolo Cancer Institute

About

Stefano Ferrari is an author at Istituto Ortopedico Rizzoli specializing in medicine, oncology, and surgical oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	43	71	5.9K
2	Health Sciences	15	16	840
3	Engineering	1	1	13
4	Public Health	1	1	30
5	Biology	1	1	13

Stefano Ferrari

161

Publications

15.6K

Citations

H-Index

Page 1

	Year	Citations
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up Paolo G. Casali, N. Abecassis, Sebastian Bauer, Annals of Oncology	2018	1.6K
Bone sarcomas: ESMO–PaedCan–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up Paolo G. Casali, Stefan Bielack, N. Abecassis, Annals of Oncology	2018	618
Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial Alessandro Gronchi, Stefano Ferrari, Vittorio Quagliuolo, The Lancet Oncology Tumor BiologySurgical OncologyMalignant DiseaseMedicineStandard Chemotherapy	2017	473
Long-Term Outcome for Patients With Nonmetastatic Osteosarcoma of the Extremity Treated at the Istituto Ortopedico Rizzoli According to the Istituto Ortopedico Rizzoli/Osteosarcoma-2 Protocol: An Updated Report Gaetano Bacci, Stefano Ferrari, Franco Bertoni, Journal of Clinical Oncology	2000	446
Neoadjuvant Chemotherapy With High-Dose Ifosfamide, High-Dose Methotrexate, Cisplatin, and Doxorubicin for Patients With Localized Osteosarcoma of the Extremity: A Joint Study by the Italian and Scandinavian Sarcoma Groups Stefano Ferrari, Sigbjørn Smeland, Mario Mercuri, Journal of Clinical Oncology	2005	432
A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study Giovanni Grignani, Emanuela Palmerini, Palma Dileo, Annals of Oncology Surgical OncologyPhase Ii TrialMedicineUnresectable High-grade OsteosarcomaMetronomic Therapy	2011	353
Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial Giovanni Grignani, Emanuela Palmerini, Virginia Ferraresi, The Lancet Oncology Surgical OncologyMedicineStandard TreatmentNon-randomised Phase 2Cancer Treatment	2014	328
Prognostic Factors in Nonmetastatic Ewing’s Sarcoma of Bone Treated With Adjuvant Chemotherapy: Analysis of 359 Patients at the Istituto Ortopedico Rizzoli Gaetano Bacci, Stefano Ferrari, Franco Bertoni, Journal of Clinical Oncology	2000	324
Postrelapse Survival in Osteosarcoma of the Extremities: Prognostic Factors for Long-Term Survival Stefano Ferrari, A Briccoli, Mario Mercuri, Journal of Clinical Oncology	2003	312
Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin Gaetano Bacci, Piero Picci, Stefano Ferrari, Cancer	1993	296

Page 1